Press Releases
-
NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer
April 12, 2019 by NanOlogy
-
NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium
February 13, 2019 by NanOlogy
-
NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference
February 5, 2019 by NanOlogy
-
Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery
October 30, 2018 by NanOlogy
NanOlogy in the News
- NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
- Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
- Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
- Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug
- Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer
Upcoming NanOlogy Events
Publications & Presentations
- BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy
- ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts
- SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model
- ASCO 2018 Poster: NanoPac Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model
Media Contacts
Opus Biotech Communications
Daniel Eramian 425-306-8716 danieleramian@comcast.net
Charles Craig 404-245-0591 charles.s.craig@gmail.com
